Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948865 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer and Cancer, Lung, sponsored by Conjupro Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 14
- Study locations
NCT05948865: Recruiting Phase 1 study of Cancer and Cancer, Lung, sponsored by Conjupro Biotherapeutics.
NCT05948865 is a Phase 1 study of Cancer and Cancer, Lung that is actively recruiting participants, run by Conjupro Biotherapeutics. The registered enrollment target is 132 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948865, a Phase 1 study of Cancer and Cancer, Lung, is actively recruiting participants, sponsored by Conjupro Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) * To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B) * To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To correlate preliminary efficacy with mutations in a biomarker called EGFR Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
Primary Outcome
To determine the recommended dose of CPO301 to be used as monotherapy in Part B (RP2D)
Conditions Studied
Interventions
- DRUG CPO301
Study Locations (14)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
Florida
- AdventHealth Cancer Institute - Celebration
- Florida Cancer Specialists - Sarasota
Ontario
- Juravinski Cancer Centre - Hamilton
- Princess Margaret Cancer Centre - University Health Network - Toronto
Colorado
- Sarah Cannon Research Institute (SCRI) at HealthONE - Denver
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- NEXT Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT05948865 shows while recruiting
NCT05948865 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which CPO301 is the first listed.
NCT05948865 lists 14 locations in 10 states (California, Florida, Ontario).
Frequently Asked Questions
What is clinical trial NCT05948865 about?
NCT05948865 is a clinical study titled "A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors". The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to ...
What is the current status of trial NCT05948865?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2023-06-06. Estimated completion is 2027-08.
What conditions does trial NCT05948865 study?
This clinical trial studies the following conditions: Cancer, Cancer, Lung.
What interventions are being tested in trial NCT05948865?
The interventions under investigation include: CPO301 (DRUG).
Who is sponsoring clinical trial NCT05948865?
This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948865 being conducted?
This trial has 14 study locations across California, Colorado, Florida, New Hampshire, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05948865's enrollment target sits among peer trials
132 276th of 615 higher than 340 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI